anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: To introduce a two-dimensional sonographic method to assess the fetal anus, and to evaluate the feasibility of this method to diagnose anal atresia prenatally and identify the presence or absence of anoperineal fistula (in males) and anovestibular fistula (in females).
METHODS: This was an observational study of suspected cases of anal atresia referred to a single center in Israel between August 2018 and October 2023. In addition to conventional evaluation of the perineum in the axial plane, fetuses referred to our center for suspected malformation were scanned with a new method termed the 'infracoccygeal/transperineal window'. This window consisted of a midsagittal view of the fetal pelvis, including the distal rectum and the anal canal. Normal anatomy was confirmed when the anal canal was continuous with the rectum and terminated at the expected location on the perineum. In female fetuses, the normal anal canal runs parallel to the vaginal canal and diverges posteriorly, terminating at the perineal skin, distant from the vestibule. In male fetuses, the normal anal canal diverges posteriorly in relation to the corpora cavernosa, terminating at the perineal skin, distant from the scrotum. High anal atresia was identified when a blind-ending rectal pouch was demonstrated in the pelvis without a fistula to the perineum or vestibule. Low anal atresia was determined when a rectal pouch was continuous with an anteriorly deflected fistula. In females, the fistula converges with the vaginal canal, terminating at the vestibule; in males, the fistula deflects anteriorly, terminating at the base of the scrotum. Postnatally, the diagnosis and type of anal atresia were confirmed through physical examination with direct visualization of the fistula, radiographic studies, surgical examination and/or postmortem autopsy.
RESULTS: Of the 16 fetuses diagnosed prenatally with anal atresia, eight were suspected to have low anal atresia and eight were suspected to have high anal atresia. The median gestational age at diagnosis was 23 (range, 14-37) weeks. All cases showed additional structural malformation. Eleven patients opted for termination of pregnancy, of which four had low anal atresia and seven had high anal atresia. Postnatal confirmation was not available in four cases due to curettage-induced mutilation or in-utero degradation following selective termination of the affected twin, leaving 12 cases for analysis, of which seven were diagnosed with low anal atresia and five with high anal atresia. In these 12 cases, all prenatal diagnoses were confirmed as correct, rendering 100% sensitivity and 100% specificity in this high-risk fetal population.
CONCLUSIONS: The infracoccygeal/transperineal window is an effective method to detect and classify the level of anal atresia prenatally. This may improve prediction of postnatal fetal continence and optimize prenatal counseling. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.
SPRINT PNS System will be offered to patients with postoperative knee pain following primary unilateral total knee arthroplasty (TKA) who meet eligibility criteria and consistent with established coverage policy. SPRINT PNS System will be implanted for 60 days. At the discretion of the physician, the first lead may be placed to stimulate the nerve innervating the region of greatest pain. If pain is not adequately addressed by the first lead when assessed at 10 days, a second lead may be placed approximately 2 weeks following the initial lead placement.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients with progressive disease crossover to arm II.
The present invention relates to a use of a novel compound, for preventing, improving or treating amyotrophic lateral sclerosis (ALS). The present inventors have found that SOD1 aggregation is one of the important causes of ALS, and have proposed the possibility that WT-SOD1 aggregation, caused by suppressing the regulation of intracellular stress or TDP-43, may be a cause of sALS. In addition, the present inventors have discovered the novel compound PRG-A-01 (SLC-B036) as a SOD1 aggregation and misfolding inhibitor. The compound exhibited a protective effect against muscle weakness and movement disorder in an ALS mouse model. According to the result of a histological analysis, intraspinal nerves were maintained by means of a treatment using PRG-A-01 (SLC-B036). In addition, the present inventors have obtained a candidate compound (PRG-A-04) which can be a more optimized drug. Consequently, the compound of the present invention may be usefully employed in developing a therapeutic agent for ALS.
FIELD: medicine. SUBSTANCE: protein (molecular mass is 37-40 kDa) carrying out pore-forming function in cell wall of Pseudomonas mallei and purified from cytoplasmic proteins and peptidoglycan is administrated to glanders-sensitive animals by subcutaneously route (dose is 100-30000 mcg protein per 1 kg animal mass). After 12-24 hr protein is administrated again. Treatment is carried out for at least 2 days after infection or up to disappearance of clinical symptoms at developed glanders infection. Method provides 100% survival of golden hamsters infected with 10-20 lethal doses of agar culture of high-virulent strain P. mallei (subcutaneously) and 52% golden hamsters with developed glanders infection at 100% death of untreated animals. EFFECT: enhanced effectiveness of glanders treatment. 2 tbl
Identifying organisms directly from positive blood culture bottles using matrix-assisted laser desorption-ionisation time-of-flight mass spectrometry (MALDI-TOF MS) has many advantages to patients, clinical services, and laboratories. However, few published methods have demonstrated good performance using the current BioMérieux culture bottles and MALDI-TOF system: BacT/Alert FAN plus and Vitek MS. The effect of transporting bottles on test performance has not been assessed for any direct-from-bottle MS method. In this study, 802 positive blood culture bottles were analysed including 234 requiring inter-laboratory transport, using a method involving protein extraction with formic acid and acetonitrile. Correct identification rates were high for Staphylococcus aureus (58/58 of new diagnostic samples), Enterococcus faecalis (27/27), Gram-negative bacilli (160/176, 90.1%), and coagulase-negative Staphylococcus species (108/132, 81.8%). Three false identifications were made, none with clinical significance. For Gram-positive cocci in pairs or chains, more correct identifications were made from bottles analysed immediately compared to transported bottles (67% vs 44%, p=0.016), and longer transport time was associated with slightly lower probability of correct identification (OR 0.984 per additional hour, p=0.040). Transportation was not associated with a difference for other organism types. This technique is a vastly more cost-effective alternative to molecular techniques for rapid identification of bacteraemia isolates, and performance is minimally affected by inter-laboratory transport of bottles at ambient temperature.
Assessments of arterial and venous blood gases are required to understand the function of respiratory organs in animals at different stages of development. We measured blood gases in the arteries entering and veins leaving the chorioallantoic membrane (CAM) in embryonic alligators (Alligator mississippiensis). The CAM accounts for virtually all gas exchange in these animals, and we hypothesized that the CAM vasculature would be larger in eggs incubated in hypoxia (10% O2 for 50% or 70% of incubation), which would be reflected in a lower partial pressure of CO2 (PCO2). Contrary to this hypothesis, our measurements revealed no effects of hypoxic incubation on PCO2, and seemingly no increase in vascularization of the CAM in response to incubation in 10% O2. PCO2 was lower on the venous side, but only significantly different from arterial blood at 70% of incubation. The calculated blood flow to the CAM increased with development and was lower in both groups of alligators that had been incubated in hypoxia. Future studies should include measurements of blood parameters taken from embryos held in conditions that mirror incubation O2 levels, in combination with direct measurements of CAM artery blood flow.
PURPOSE:To enable exact and easy measurement by using the fixed phase carrier of antimonoclonal PIVKA-II in the stage of measuring PIVKA-II (prothrombin precursor material and said material of which the degree of carboxylation of the residual group of the glutamic acid thereof is incomplete). CONSTITUTION:PIVKA-II is extracted from the blood plasma of a person who takes warfarin and after refining, the PIVKA-II is dosed to a mouse and the spleen cells are extracted. Antimonoclonal PIVKA-II antibody is obtd. by a cell fusion method. The antibody is fixed to the well of a microtiter plate for an enzyme immunoassay. A specified amt. of the test blood plasma and suitable enzyme labeled antihuman prothrombin antibody, for example, antihuman prothrombin rabbit IgG are brought into reaction with said well and thereafter the activity of the labeling enzyme bound to the fixed carrier is determined by measuring the density of the coloring by the enzyme substrate and the coloring reagent and is contrasted with the calibration curve obtd. preliminarily with the known PIVK-II, by which the PIVKA-II is exactly and accurately measured. The method and reagent are thus utilized for eartly location of the hemorrhagic disease owing to lack of vitamin K, etc.
PURPOSE: To improve antifoulancy by manufacturing a orthodontic appliance including a ligator, a rotational wedge, a redressment module, etc., by using specified substances and providing a specified color difference. CONSTITUTION: A ligator 10 for orthodontic appliance is manufactured by using one or more substances among thermoplastic rubber block copolymer, polyurethane, polyurea, polyurethane/urea, silicone substance, ethylene-propylene dimer rubber, ethylene-propylene monomer rubber and fluoroelastomer. In the ligator 10, when the thickness is 2mm and an aperture for illumination of 2.5mm is used, the Hunter's color difference is at most 30 in comparison with a Hunter's standard white tile. In addition, in comparison with a substance before immersion in a mustard soln., the Hunter's color difference becomes at most 33 after it is immersed in the mustard soln. for 30min. It is possible thereby to improve antifoulancy to foods and drinks such as musturd, tea and coffee.
Inflammatory bowel diseases (IBD) have a complex, poorly understood pathogenesis and lack long-lasting effective treatments. Recent research suggests that intestinal fungal dysbiosis may play a role in IBD development. This study investigates the effects of the glucocorticoid-induced leucine zipper protein (GILZp)", known for its protective role in gut mucosa, and a yeast extract (Py) with prebiotic properties, either alone or combined, in DSS-induced colitis. Both treatments alleviated symptoms via overlapping or distinct mechanisms. In particular, they reduced the transcription levels of pro-inflammatory cytokines IL-1β and TNF-α, as well as the expression of the tight junction protein Claudin-2. Additionally, GILZp increased MUC2 transcription, while Py reduced IL-12p40 and IL-6 levels. Notably, both treatments were effective in restoring the intestinal burden of clinically important Candida and related species. Intestinal mycobiome analysis revealed that they were able to reduce colitis-associated fungal dysbiosis, and this effect was mainly the result of a decreased abundance of the Meyerozima genus, which was dominant in colitic mice. Overall, our results suggest that combined treatment regimens with GILZp and Py could represent a new strategy for the treatment of IBD by targeting multiple mechanisms, including the fungal dysbiosis.
Automatic voice pathology detection is a research topic, which has gained increasing interest recently. Although methods based on deep learning are becoming popular, the classical pipeline systems based on a two-stage architecture consisting of a feature extraction stage and a classifier stage are still widely used. In these classical detection systems, frame-wise computation of mel-frequency cepstral coefficients (MFCCs) is the most popular feature extraction method. However, no systematic study has been conducted to investigate the effect of the MFCC frame length on automatic voice pathology detection. In this work, we studied the effect of the MFCC frame length in voice pathology detection using three disorders (hyperkinetic dysphonia, hypokinetic dysphonia and reflux laryngitis) from the Saarbrücken Voice Disorders (SVD) database. The detection performance was compared between speaker-dependent and speaker-independent scenarios as well as between speaking task -dependent and speaking task -independent scenarios. The Support Vector Machine, which is the most widely used classifier in the study area, was used as the classifier. The results show that the detection accuracy depended on the MFFC frame length in all the scenarios studied. The best detection accuracy was obtained by using a MFFC frame length of 500 ms with a shift of 5 ms.
PURPOSE: An anti-inflammatory composition containing acid polysaccharide of green tea is provided to relieve skin irritation, pruritus, and inflammation and to treat and prevent inflammatory dermatitis. CONSTITUTION: An acid polysaccharide having a function of suppressing inflammation is isolated from green tea. The acid polysaccharide is isolated by extracting with hot water and performing ultrafiltration and ethanol precipitation. The acid polysaccharide is rhamnose, arabinose, ribose, xylose, glucose, mannose and D-galactose. A pharmaceutical composition for preventing or treating inflammatory dermatitis contains 0.05-50 weight% of acid polysaccharide as an active ingredient. A cosmetic composition having function of suppressing inflammation contains 0.05-5 weight% of acid polysaccharide based on total weight. The cosmetic composition is used in the form of skin softener, nutrition lotion, massage cream, moisture cream, nutrition cream, pack, gel, body lotion, body cream, body oil, shampoo, and body cleanser.
This invention relates to a new method for treating or preventing brain damage caused by NMDA receptor hypofunction (NR/hypo), using drugs such as lisuride which stimulate (agonize) activity at the 5HT-2A class of serotonin receptors, but which do not cause hallucinations. Data disclosed herein indicate that stimulation of both 5HT-2A and 5HT-2C receptors causes hallucinations, while stimulation of 5HT-2A receptors but not 5HT-2C receptors does not. Accordingly, to be useful herein, non-hallucinatory 5HT-2A agonists should either (1) antagonize (suppress) activity at 5HT-2C receptors, or (2) have no significant effect on activity at 5HT-2C receptors. Selective non-hallucinatory 5HT-2A agonists can be used in either of two treatment methods disclosed herein. One such treatment comprises administering a 5HT-2A receptor agonist as a "safener drug" which accompanies an NMDA antagonist drug that is being used for a therapeutic purpose. Another method disclosed herein involves the use of a 5HT-2A agonist drug, by itself, to combat a naturally-occurring form of NMDA receptor hypofunction which occurs in people suffering from schizophrenia. Although 5HT-2A agonists would not be optimally effective in treating long-standing cases of chronic schizophrenia, where pathological changes in the brain have already reached maximal or severe levels, 5HT-2A agonists can be administered early in the illness, such as at the first signs of schizophrenic illness, and continuously thereafter to prevent the development or worsening of pathological brain dysfunction and the resulting psychosis.
<P>PROBLEM TO BE SOLVED: To provide a single component liquid pharmaceutical composition for administration to a mucosal surface, able to gelate at a site of application or be constituted to gelate.  <P>SOLUTION: The liquid pharmaceutical composition comprises a therapeutic agent and a pectin with a low degree of esterification and gelates at the site of application in a condition of the absence of an extraneous source of divalent metal ions. The mucosal surface is preferably the nasal cavity, the vagina, the rectum, the back of the throat or the eye. The degree of esterification is <50%. The concentration of pectin is 1-100 g/L. The therapeutic agent is an antiviral agent, a vaccine, a decongestant, a contraceptive or the like.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Vitellogenin is a protein specific of vertebrate oviparous females, which levels are increased during the cycle of ovarian maturation. This protein is a glycol-phospho-lypo-caroteno-protein complex, which is produced in the liver and travels through the plasma for being incorporated to the ovary, which molecular weight ranges from 250 kDa to 600 kDa. Consequently, this protein can be used as a biomarker for sexing fish, such as catan fish that does not present sexual dimorphism. The present application details the manufacture of a test strip for sexing lepisosteidae fish in situ and avoiding slaughter of specimens. The invention is advantageous in that it allows the sex of catan fish to be identified without slaughtering the same, since these animals are a threatened species. On the other hand, this type of strips facilitates the identification of the sex of ornamental fish, which is an important issue for reproduction purposes in species held in captivity.
UNLABELLED: Benign acute childhood myositis is a benign phenomenon often associated with influenza in children. The aim of this scoping review was to analyze the typical clinical picture and characteristics of benign acute childhood myositis patients. Furthermore, we aimed to analyze the epidemiology and viral findings. We performed a systematic scoping review. We searched PubMed, Scopus, Web of Science, and CINAHL databases in August 2023. We included observational studies that focused on children and reported at least 10 children. Our main outcome was to describe the typical clinical picture of benign acute childhood myositis patients. Furthermore, we aimed to report the typical laboratory findings and virus findings. A total of 211 studies were screened, and 22 studies were included in this review. The included studies were mainly from Europe (13 studies) and Asia (5 studies). Two studies were prospective, and the rest were retrospective. The mean age of the patients was 6.8 (CI 5.8-7.8) years. Benign acute childhood myositis appeared to be more prevalent among boys in all studies. The most prevalent symptoms were bilateral leg pain (pooled prevalence 92%), followed by fever (80%) and inability to walk (56%). Hospitalization rates varied between 4 and 100%, and the mean hospital stay was 3.6 (CI 3.3-3.9) days. Influenza B was the most common virus detected, followed by influenza A. Other reported viruses included herpes simplex, coxsackie-, enteroviruses, adeno-, respiratory syncytial, and parainfluenza viruses. All studies reported creatinine kinase levels, and the reported mean values varied between 100 and 4000 U/L, whereas only five studies reported C-reactive protein which was only slightly elevated.
CONCLUSION: According to a systematic assessment of published literature, benign acute childhood myositis patients were typically school-aged children, presenting with bilateral leg pain, fever, and inability to walk. Influenza A and B were the most reported viruses, but multiple other viruses have been associated with benign acute childhood myositis. These patients have high creatinine kinase values, but their hospital stay was rather short. Overall, this review provides important information for clinicians on the characteristic presentation of benign acute childhood myositis, and these findings may help to better identify these patients and reduce unnecessary tests.
WHAT IS KNOWN: • Benign acute childhood myositis has been mainly associated with influenza viruses, especially B influenza. • Typical patients have been reported to be under school-aged children, and boys have been reported to have a higher incidence.
WHAT IS NEW: • Many non-influenza viruses were also associated with benign acute childhood myositis, such as herpes simplex, coxsackie-, entero-, adeno-, respiratory syncytial, and parainfluenza viruses. • Typical symptoms are bilateral calf pain, fever, and inability to walk and creatine kinase levels were reposted to be increased.
This is a multicentre, open label, single-arm study in approximately 20 adult patients (18 - 75 years old) designed to evaluate the Impact on lifestyle of a new thermo stable formulation of epoprostenol sodium in subjects with Pulmonary Arterial Hypertension (PAH). The co-primary objectives are 1) to describe the effect of the new thermo stable formulation of epoprostenol sodium on quality of life and 2) to determine the dose titration requirement in patients switching from the currently marketed FLOLAN (epoprostenol sodium) to the new thermo stable formulation. Secondary objectives include assessing the safety, tolerability and efficacy of the thermo stable formulation of epoprostenol sodium and the exploratory objective is to evaluate the effect of the new thermo stable formulation of epoprostenol sodium on haemodynamic parameters in a subset of subjects.

Subjects who are already receiving FLOLAN (epoprostenol sodium) for the treatment of PAH and have been on a stable dose for at least 3 months and on stable doses of other PAH treatments for at least 30 days prior to screening will be enrolled. After a screening visit, eligible subjects will have a 4-week run-in period with their existing FLOLAN (epoprostenol sodium) treatment. At the end of the 4-week period, they will be admitted to the clinic for baseline assessments and for switching to study medication (the new thermo stable formulation of epoprostenol sodium). Subjects will remain in hospital for a minimum of 6 hours to ensure clinical and hemodynamic stability prior to discharge. Subjects may stay in hospital for up to 24-48 hours after switching to the new thermo stable formulation of epoprostenol sodium at the discretion of the investigator. Dose titration requirement will be assessed at the time of discharge. Haemodynamic parameters will be obtained in a subgroup of subjects enrolled in centres where the collection of haemodynamic data is considered part of the standard of care. Subjects will receive the study medication as a continuous intravenous infusion for a 4-week treatment period. Those who complete the 4-week treatment period will have the option of entering an extension phase of the study to continue receiving the new formulation.